PCL, Inc. (KOSDAQ:241820)

South Korea flag South Korea · Delayed Price · Currency is KRW
302.00
-5.00 (-1.63%)
Mar 21, 2025, 5:32 PM KST
-78.93%
Market Cap 17.87B
Revenue (ttm) 7.88B
Net Income (ttm) -13.28B
Shares Out 59.17M
EPS (ttm) -186.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 237,458
Average Volume 917,759
Open 307.00
Previous Close 307.00
Day's Range 300.00 - 307.00
52-Week Range 295.00 - 2,190.00
Beta 0.19
RSI 24.19
Earnings Date Mar 21, 2025

About PCL, Inc.

PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. The company offers HiSU solution, an automated multi-immune diagnostic system that performs various diagnostics, high-speed tests including blood screening, multiple cancer screening, autoimmune testing, etc. It also provides antigen and antibody diagnostic kits, including PCLOK II anti-HIV/HCV/syphilis, and PCLOK II HBsAg/HIV p24. In addition, the company offers platform services, such as SG ID for identifying novel target substances. Further, it offers covi... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2008
Employees 31
Stock Exchange KOSDAQ
Ticker Symbol 241820
Full Company Profile

Financial Performance

In 2023, PCL, Inc.'s revenue was 8.43 billion, a decrease of -77.35% compared to the previous year's 37.22 billion. Losses were -20.32 billion, 405.7% more than in 2022.

Financial Statements

News

There is no news available yet.